



## **Statins for all?**

**Applying contemporary recommendations for statin therapy comparing QRISK3 to ASCVD AHA/ACC and impact on primary prevention prescribing in people living with HIV.**

**Vladislav Zlatkin<sup>1</sup>**

(He/Him)

Alan Hunter<sup>2</sup>, Fiona Burns<sup>1,2</sup>, Tristan J Barber<sup>1,2</sup>, Roby Rakhit<sup>1,2</sup>

*1. University College London. 2. Royal Free Hospital London*



## **Conflict of Interest**

In relation to this presentation, I declare that I have no conflict of interest

Speakers are required by the Federation of the Royal Colleges of Physicians to disclose conflicts of interest at the beginning of their presentation, with sufficient time for the information to be read by the audience. They should disclose financial relationships with manufacturers of any commercial product and/or providers of commercial services used on or produced for patients relating to the 36 months prior to the event. These include speaker fees, research grants, fees for other educational activities such as training of health professionals and consultation fees. Where a speaker owns shares or stocks directly in a company producing products or services for healthcare this should also be declared.



Mon 29<sup>th</sup> April – Wed 1<sup>st</sup> May  
Birmingham, UK



## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 24, 2023

VOL. 389 NO. 8

### Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

Steven K. Grinspoon, M.D., Kathleen V. Fitch, M.S.N., Markella V. Zanni, M.D., Carl J. Fichtenbaum, M.D., Triin Umbleja, M.S., Judith A. Aberg, M.D., Edgar T. Overton, M.D., Carlos D. Malvestutto, M.D., M.P.H., Gerald S. Bloomfield, M.D., M.P.H., Judith S. Currier, M.D., Esteban Martinez, M.D., Ph.D., Jhoanna C. Roa, M.D., Marissa R. Diggs, B.A., Evelynne S. Fulda, B.A., Kayla Paradis, M.B.A., Stephen D. Wiviott, M.D., Borek Foldyna, M.D., Sara E. Looby, Ph.D., Patrice Desvigne-Nickens, M.D., Beverly Alston-Smith, M.D., Jorge Leon-Cruz, M.S., Sara McCallum, M.P.H., Udo Hoffmann, M.D., M.P.H., Michael T. Lu, M.D., M.P.H., Heather J. Ribaldo, Ph.D., and Pamela S. Douglas, M.D., for the REPRIEVE Investigators\*

## Median 10-year CVD risk – 4.5%



ASCVD  
Risk Estimator



[Home](#) [Contact Us](#) [Login](#) [Join BHIVA](#)

[Clinical Guidelines](#) > [Rapid Guidance](#) > [BHIVA rapid guidance on the use of sta](#) ▾

### BHIVA rapid guidance on the use of statins for primary prevention of cardiovascular disease in people living with HIV

## 10-year CVD risk $\geq 5\%$ , over 40yo

#### About you

Age (25-84):

Sex:  Male  Female

Ethnicity:

UK postcode: leave blank if unknown

Postcode:

#### Clinical information



## Afya Clinic – Annual health review.

- 198 records reviewed
- 88 people eligible ( $\geq 40$  yo, availability of data, no CVD)
- AHA/ACC vs QRISK3
- Statin prescriptions

		Ethnic White	53/88 (60.2%)
		Ethnic Black	21/88 (23.9%)
		Ethnic Asian	5/88 (5.7%)
		Other ethnicity	9/88 (10.2%)
		Hypertension	22/88 (25%)
		Pre-hypertension	36/88 (40.9%)
		Total Cholesterol $\geq 5$ mmol/L	43/88 (48.9%)
		Smokers	14/88 (15.9%)
		Median HIV duration	21.1(IQR, 14.7)
		Median CD4 count	642 (IQR, 309.5)
		Statin prescription	26/88 (29.5%)
Male	67/88 (76.1%)		
Female	21/88 (23.9%)		
Age (years old)	58.2 (IQR, 11)		
Range	40-79		






Mon 29<sup>th</sup> April – Wed 1<sup>st</sup> May  
Birmingham, UK




AHA/ACC	QRISK3
10.3% (S.D, 8.8)	12.6% (S.D, 10.5)

- Observational design
- Not powered


CVD risk by demographic



Statin eligibility (QRISK3 ≥10) vs statin prescription by age.



Statin use vs eligibility (QRISK ≥ 5%) by demographic





## References

- 1) Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med [Online]. 2023;389(8):687–99. Available from: <http://dx.doi.org/10.1056/nejmoa2304146>
- 2) AHA/ACC. ASCVD Risk Estimator + [Online]. Acc.org. [cited Apr 10 2024]. Available from: <https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/>
- 3) QRISK3 [Online]. Qrisk.org. [cited Apr 10 2024]. Available from: <https://www.qrisk.org/index.php>
- 4) Michael Pignone, Christopher P Cannon. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. UpToDate [Online]. Mar 2024 [cited Apr 10 2024];46(2):20–20. Available from: <https://www.uptodate.com/contents/low-density-lipoprotein-cholesterol-lowering-therapy-in-the-primary-prevention-of-cardiovascular-disease>
- 5) NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE. Dec 2023 [cited Apr 10 2024]; Available from: <https://www.nice.org.uk/guidance/ng238/chapter/Recommendations>
- 6) BHIVA. BHIVA rapid guidance on the use of statins for primary prevention of cardiovascular disease in people living with HIV. Bhiva.org. Nov 2023 [cited Apr 10 2024]. Available from: <https://www.bhiva.org/BHIVA-rapid-guidance-on-the-use-of-statins-for-primary-prevention-of-cardiovascular-disease>